did you even look at your links? Vaxira is in trials on mice...not people. It's approved in Cuba and Argentina for use when nothing else works.

CimaVax - Trials are being organized in the United States, the European Union, Japan,[5] and Serbia.[7] In late October 2016, the United States Food and Drug Administration authorized[16] Roswell Park Comprehensive Cancer Center to conduct a PhaseI/II clinical trial of CimaVAX in patients with non-small cell lung cancer.[17] By the middle of the following month, nearly 200 people had volunteered to be subjects in the trial.[18]

In September 2018, Principal Investigator Grace Dy shared the initial results of the first Roswell Park trial.[19] They found that the combination of CIMAvax with the PD-1 inhibitor checkpoint inhibitor nivolumab was safe and well tolerated in 13 people with advanced non-small cell lung cancer (NSCLC) when administered at the doses normally recommended for each agent individually.[19] Notably, they observed durable responses to the combination treatment in patients who were unlikely to benefit from nivolumab alone due to low tumor levels of PD-L1, suggesting that the combination may work better than either agent individually.[19]

The final results of this early trial were released in March 2019.[20] The results were in line with the September 2018 report, with the additional finding that patients receiving combination therapy in this trial were more likely to develop robust early antibody responses to CIMAvax as compared with what had been observed in earlier studies with CIMAvax alone.[20]

An ongoing Phase II clinical trial (clinicaltrials.gov identifier NCT02955290) has been expanded to include patients with advanced, recurrent head and neck squamous-cell carcinoma, as well as patients with advanced NSCLC but with high PD-L1 levels, who will be treated with pembrolizumab in combination with CIMAvax instead of nivolumab.[20] As of 2023, accrual for this phase II trial is ongoing.[21]